A NATIONWIDE STUDY OF NEWLY DIAGNOSED NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA OVER TWO DECADES

EHA Library, Katrin Bamdeg-Hvolbek, 419191

COMBINATION OF BRENTUXIMAB VEDOTIN AND PEMBROLIZUMAB BEFORE INTENSIFICATION WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA.

EHA Library, Hanne Massa, 419192

BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: SEVEN-YEAR OVERALL SURVIVAL ANALYSIS FROM THE ECHELON-1 STUDY

EHA Library, John Radford, 419193

OUTCOME OF PATIENTS WITH LIMITED-STAGE HODGKIN LYMPHOMA (HL) ENROLLED IN THE EORTC/LYSA/FIL H10 AND PROGRESSED/RELAPSED AFTER INITIAL THERAPY

EHA Library, Manuel Gotti, 419194

TIMING MATTERS: IMPACT OF EARLY HISTOLOGICAL TRANSFORMATION ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL) PATIENTS: A MULTICENTRE ANALYSIS

EHA Library, Andrea Franch, 419195

TUMOR ASSOCIATED MACROPHAGES’ CYTOKINES; CD163, CCL4 AND CCL2, AS POSSIBLE NEW BIOMARKERS IN WALDENSTROM’S MACROGLOBULINEMIA.

EHA Library, Alexandros Gkiokas, 419196

SAFETY AND EFFICACY RESULTS OF A PHASE 1 STUDY OF THE NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) FOR RELAPSED/REFRACTORY WALDENSTRÖM'S MACROGLOBULINEMIA

EHA Library, Chan Y. Cheah, 419197

RELAPSE PATTERNS AND OUTCOMES OF PATIENTS WITH FOLLICULAR LYMPHOMA ACHIEVING COMPLETE METABOLIC RESPONSE AFTER INDUCTION THERAPY. A FIL FOLL12 SUB-STUDY.

EHA Library, Maria Elena Nizzoli, 419198

COMBINATION TREATMENT WITH NOVEL BCL-2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MCL

EHA Library, Constantine S. Tam, 419199

WAVE STUDY, A RETROSPECTIVE OF FILO TRIAL : PATIENTS WITH RELAPSE WALDENSTRÖM'S MACROGLOBULINEMIA TREATED BY VENETOCLAX IN REAL LIFE

EHA Library, Mathilde Vonfeld, 419200

PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA TREATED WITH EPCORITAMAB

EHA Library, Wojciech Jurczak, 419201

SPLENOMEGALY AT THE TIME OF LGLL DIAGNOSIS IS ASSOCIATED WITH POOR DISEASE OUTCOMES AND EXPANSION OF LGLL CLONES.

EHA Library, Ahmad Kiwan, 419202

CLINICAL FEATURES AND GENETIC ALTERATIONS ASSOCIATED WITH HISTOLOGIC GRADING OF FOLLICULAR LYMPHOMA

EHA Library, Huilai Zhang, 419203

BENEFIT OF RITUXIMAB MAINTENANCE AFTER FIRST-LINE BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Yucai Wang, 419204

IBRUTINIB, LENALIDOMIDE AND RITUXIMAB IN RELAPSED MANTLE CELL LYMPHOMA - LONG TERM FOLLOW-UP OF THE NORDIC LYMPHOMA GROUP MCL6 PHILEMON TRIAL

EHA Library, Elin Forsgren, 419205

PRELIMINARY EFFICACY AND SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB-16673 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) INDOLENT NHL: RESULTS FROM THE PHASE 1 BGB-16673-101 STUDY

EHA Library, Chan Y. Cheah, 419206

ZR STUDY：A PROSPECTIVE PHASE II STUDY OF ZANUBRUTINIB-RITUXIMAB INDUCTION WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED MANTLE CELL LYMPHOMA

EHA Library, Chang-Ju Qu, 419207

MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VS MOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES

EHA Library, Alexey Danilov, 419208

RESULTS FROM THE FOLLICULAR LYMPHOMA (FL) OUTCOMES IN RELAPSED/REFRACTORY (R/R) PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA) STUDY

EHA Library, Emmanuel Bachy, 419209

MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB VERSUS REAL-WORLD CHEMOIMMUNOTHERAPY (CIT) OR CHEMOTHERAPY (CHEMO) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

EHA Library, Renata Walewska, 419210

REAL-WORLD EVALUATION OF TREATMENT PATTERN, TIME TO NEXT TREATMENT, HEALTHCARE RESOURCE UTILIZATION, AND COST OF CARE IN FOLLICULAR LYMPHOMA

EHA Library, Sameh Gaballa, 419211

TP53 AND CDKN2A DISRUPTIONS ARE INDEPENDENT PROGNOSTIC DRIVERS IN MANTLE CELL LYMPHOMA: LONG TERM OUTCOME OF THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL

EHA Library, Riccardo Moia, 419212

SUBGROUP ANALYSES IN PATIENTS WITH R/R MCL TREATED WITH LISOCABTAGENE MARALEUCEL BY PRIOR LINES OF THERAPY AND RESPONSE TO BRUTON TYROSINE KINASE INHIBITOR FROM THE TRANSCEND NHL 001 MCL COHORT

EHA Library, Manali Kamdar, 419213

RESPONSE-ADAPTED TREATMENT WITH MOSUNETUZUMAB WITH OR WITHOUT OBINUTUZUMAB AND POLATUZUMAB VEDOTIN IN TREATMENT NAÏVE FOLLICULAR AND MARGINAL ZONE LYMPHOMA: INTERIM RESULTS AND PHASED-SEQ MRD ANALYSIS

EHA Library, Ryan Lynch, 419214

EFFICACY AND SAFETY OF IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) AND TP53 MUTATIONS IN THE SYMPATICO STUDY

EHA Library, Wojciech Jurczak, 419215

CLINICAL CHARACTERISTICS AND OUTCOMES OF MCL PATIENTS AGED 80 YEARS AND OLDER

EHA Library, Simon Pahnke, 419216

VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL OR ARI-0001) IN RELAPSED / REFRACTORY ADULT FOLLICULAR LYMPHOMA

EHA Library, Nuria Martinez-Cibrian, 419217

AZD0486, A NOVEL CD19XCD3 T-CELL ENGAGER, SHOWS DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATE ON EFFICACY AND SAFETY

EHA Library, Sumana Devata, 419218

SAFETY AND EFFICACY OF GOLCADOMIDE, A POTENTIAL FIRST-IN-CLASS CELMOD AGENT ± RITUXIMAB IN A PHASE 1/2 OPEN-LABEL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

EHA Library, Julio Chavez, 419219

COMPARATIVE EFFECTIVENESS OF EPCORITAMAB VERSUS REAL-WORLD USUAL CARE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Tycel Phillips, 419220

PATIENT CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL) IN THE UNITED STATES (US), CANADA, AND EUROPE: A PANEL-BASED CHART REVIEW STUDY

EHA Library, Craig Portell, 419221

SAFETY AND PRELIMINARY EFFICACY OF BI-1206, AN ANTIBODY TO CD32B (FCGRIIB), GIVEN IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Mariana Beatriz Bastos, 419222

EPIDEMIOLOGICAL FEATURES AND PROGNOSIS FOR PRIMARY GASTROINTESTINAL FOLLICULAR LYMPHOMA

EHA Library, Huilai Zhang, 419223

UNDETECTABLE MEASURABLE RESIDUAL DISEASE (MRD) IS ASSOCIATED WITH IMPROVED LONG-TERM OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) TREATED WITH CHEMO-IMMUNOTHERAPY: RESULTS FROM SWOG S0016

EHA Library, Alexey Danilov, 419224

PRELIMINARY SAFETY AND EFFICACY OF BOVEN (ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX) FOR FRONTLINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Anita Kumar, 419225

REAL-WORLD COMPARATIVE EFFECTIVENESS OF COVALENT BRUTON TYROSINE KINASE INHIBITORS (CBTKI) AMONG PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL)

EHA Library, Tycel Phillips, 419226

THE EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS STANDARD OF CARE (SCHOLAR-5) IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES: AN INDIRECT TREATMENT COMPARISON

EHA Library, Anna Sureda Balari, 419227

ORELABRUTINIB-LENALIDOMIDE-RITUXIMAB IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): UPDATED RESULTS OF THE MULTICENTER, PHASE II POLARIS STUDY

EHA Library, Huilai Zhang, 419228

CLINICAL FEATURES, TREATMENT PATTERNS, AND OUTCOMES OF DUODENAL-TYPE FOLLICULAR LYMPHOMA WITH A LONG-TERM FOLLOW-UP OBSERVATIONAL STUDY

EHA Library, Fuka Mima, 419229

INTRAPATIENT COMPARATIVE ANALYSIS OF ZANUBRUTINIB PLUS OBINUTUZUMAB EFFICACY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA USING THE GROWTH MODULATION INDEX

EHA Library, Kamal Bouabdallah, 419230

INCIDENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA: A SINGLE CENTRE REAL-WORLD EXPERIENCE

EHA Library, Nicole Japzon, 419231

ZANUBRUTINIB IN BING-NEEL SYNDROME: EFFICACY AND TOLERABILITY

EHA Library, Josephine Vos, 419232

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) IN PREVIOUSLY UNTREATED (1L) FOLLICULAR LYMPHOMA (FL) AND EPCORITAMAB MAINTENANCE THERAPY IN FL: NOVEL RESULTS FROM EPCORE NHL‑2 ARMS 6 AND 7

EHA Library, Lorenzo Falchi, 419233

CLINICAL EFFICACY OF RUXOLITINIB IN T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA VIA A NON-TUMOR CELL AUTONOMOUS MECHANISM

EHA Library, Amira Marouf, 419234

FRONTLINE TREATMENT WITH ZANUBRUTINIB PLUS RITUXIMAB (ZR) FOLLOWED BY SHORT COURSE R-DHAOX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) – RESULTS OF PHASE II CHESS TRIAL

EHA Library, Qingqing Cai, 419235

EZH2 ABERRATIONS IN ADVANCED FOLLICULAR LYMPHOMA: FIRST TRANSLATIONAL RESULTS OF FOLL-EZ, AN ANCILLARY STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL

EHA Library, Simone Ferrero, 419236

A COMPARISON OF TREATMENT OUTCOMES BETWEEN CYCLOSPORIN AND CHEMOTHERAPY IN SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA (SPTCL): REPORT FROM THE NATIONWIDE MULTI-CENTER THAI LYMPHOMA STUDY GROUP

EHA Library, Thitirat Tirachotikul, 419237

EXTENDED FOLLOW-UP BEYOND 2.5 YEARS SHOWS LONG-TERM EFFICACY IN COMPLETE RESPONDERS FOLLOWING EPCORITAMAB MONOTHERAPY IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Catherine Thieblemont, 419238

EPCORITAMAB + GEMOX INDUCES DEEP, DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS FROM THE EPCORE NHL-2 TRIAL

EHA Library, Raul Cordoba, 419239

OUTCOMES IN PATIENTS WITH LARGE B-CELL LYMPHOMA TREATED WITH TAFASITAMAB PLUS LENALIDOMIDE POST-CD19-TARGETING CAR-T THERAPY: A LYSA STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Vincent Camus, 419240

DEFINITION AND USE OF BULKY DISEASE IN LYMPHOMA CARE: A STUDY FROM THE AUSTRALASIAN LYMPHOMA AND RELATED DISEASES REGISTRY (LARDR)

EHA Library, Eliza Chung, 419241

PREVALENCE OF CARDIOVASCULAR RISK FACTORS AND LEFT VENTRICULAR DYSFUNCTION IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA COMPARED WITH SIBLING CONTROLS

EHA Library, Suzanne Neppelenbroek, 419242

SECONDARY PRIMARY MALIGNANCIES AFTER CD19-DIRECTED CAR-T CELL THERAPY IN LYMPHOMAS: A REPORT FROM THE ITALIAN CART-SIE STUDY

EHA Library, Angelica Barone, 419243

FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS (PTS) WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: RESULTS FROM THE PHASE 2 SGN35-032 STUDY

EHA Library, Swaminathan Iyer, 419244

BRIGATINIB MONOTHERAPY IN CHILDREN WITH R/R ALK+ ALCL: PRELIMINARY RESULTS FROM THE BRIGAPED (ITCC-098) PHASE 1 DOSE-ESCALATION STUDY

EHA Library, Charlotte Rigaud, 419245

ZUMA-24 PRELIMINARY ANALYSIS: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL IN THE OUTPATIENT SETTING WITH PROPHYLACTIC CORTICOSTEROIDS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Lori Leslie, 419246

A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY WITH A PD-1 KNOCKOUT (CB-010) FOR RELAPSED/REFRACTORY B CELL NON-HODGKIN LYMPHOMA (R/R B-NHL): UPDATED PHASE 1 RESULTS FROM THE ANTLER TRIAL

EHA Library, Boyu Hu, 419247

EPCORITAMAB + R-DHAX/C ELICITS DEEP, DURABLE RESPONSES IN TRANSPLANT-ELIGIBLE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING HIGH-RISK DISEASE

EHA Library, Pau Abrisqueta, 419248

ODRONEXTAMAB DEMONSTRATES DURABLE COMPLETE RESPONSES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PROGRESSING AFTER CAR-T THERAPY: OUTCOMES FROM THE ELM-1 STUDY

EHA Library, Jean-Marie Michot, 419249

PLASMA CELL-FREE DNA AS AN ALTERNATIVE TO TISSUE DNA FOR DETECTING GENETIC ALTERATIONS OF IVLBCL

EHA Library, Chao Chen, 419250

SUPERIOR EFFECTS OF CD19/20 DUAL-TARGETING CAR-T IN PATIENTS WITH RELAPSED/REFRACTIVE B-CELL LYMPHOMA: A MULTICENTER PRELIMINARY INTERIM REPORT

EHA Library, Jiaqi Guo, 419251

ANBALCABTAGENE AUTOLEUCEL (PD-1 AND TIGIT KNOCK-DOWNED CD19 CAR-T) FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS: RESULT OF A PIVOTAL PHASE 2 STUDY.

EHA Library, Won-Seog Kim, 419252

REAL-WORLD ANALYSIS OF GLOFITAMAB FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN GERMANY, AUSTRIA AND SWITZERLAND

EHA Library, Rebecca Wurm-Kuczera, 419253

ORIENT STUDY: ORELABRUTINIB ADDITION TO R-CHOP-LIKE REGIMEN ADAPTED TO RESPONSE IN TREATMENT-NAÏVE NON-GCB DLBCL

EHA Library, Chang-Ju Qu, 419254

PHASE I-II STUDY COMBINING BRENTUXIMAB VEDOTIN WITH R-DHAP AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN CD30 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF THE HOVON 136 STUDY

EHA Library, Pieternella (Elly) Lugtenburg, 419255

GENOMIC PROFILING IN A SUBGROUP ANALYSIS OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND EXTRANODAL (EN) SITES OF INVOLVEMENT IN THE PHASE III POLA-R-CHP VERSUS R-CHOP (POLARIX) STUDY

EHA Library, Gilles Salles, 419256

PHASE 2 STUDY OF ANTI-PD-L1 ANTIBODY ATEZOLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA: NCCH1903/ATTACK STUDY

EHA Library, Shinichi Makita, 419257

COMPARISON OF ZUBERITAMAB PLUS CHOP WITH RITUXIMAB PLUS CHOP FOR THE TREATMENT OF DRUG-NAÏVE PATIENTS DIAGNOSED WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE 3 TRIAL

EHA Library, Zhi-Ming Li, 419258

VALEMETOSTAT MONOTHERAPY IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS: A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL

EHA Library, Dai Maruyama, 419259

FEASABILITY AND SAFETY DATA OF THE CHEMOTHERAPY-LIGHT COMBINATION OF RITUXIMAB, POLATUZUMAB VEDOTIN AND GLOFITAMAB IN AGGRESSIVE B-CELL LYMPHOMA PATIENTS INELIGIBLE FOR FULLY DOSED R-CHOP

EHA Library, Rebecca Wurm-Kuczera, 419260

ANALYSIS OF CCND3 MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Jin-Hua Liang, 419261

ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PROOF-OF-CONCEPT PHASE II STUDY

EHA Library, Yan Zhang, 419262

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) - FINNISH REAL-LIFE DATA WITH LONG-TERM FOLLOW-UP ON 215 SOLID ORGAN RECIPIENTS

EHA Library, Terhi Friman, 419263

THE PROGNOSTIC SIGNIFICANCE OF MYC/BCL2 DOUBLE EXPRESSION IN DIFFUSE LARGE B CELL LYMPHOMA IN THE GENETIC CLASSIFICATION ERA

EHA Library, Jin-Hua Liang, 419264

BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS– UPDATED ANALYSIS OF REAL-WORLD DATA

EHA Library, Magdalena Klanova, 419265

FRONTLINE TREATMENT CHOICES AND GENETIC CHARACTERISTICS OF PATIENTS WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA WITH SYNCHRONOUS CNS AND SYSTEMIC INVOLVEMENT.

EHA Library, Jacopo Calabrese De Feo, 419267

CD19/BCMA DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA: AN UPDATE

EHA Library, Xinfeng Chen, 419268

REAL-WORLD EXPERIENCE OF POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB AND BENDAMUSTINE IN RELAPSED AND REFRACTORY LARGE B-CELL LYMPHOMAS.

EHA Library, Michał Danecki, 419269

PREDICTING THE TRULY LOW-RISK PATIENTS WITH TNFRSF14 MUTATION USING MACHINE LEARNING ALGORITHMS IN DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Jin-Hua Liang, 419270

A VISUAL NOMOGRAM SURVIVAL PREDICTION MODEL IN ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)-RELATED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, chongling Hu, 419271

ZANUBRUTINIB, LENALIDOMIDE, RITUXIMAB, TEMOZOLOMIDE AND METHOTREXATE (RLZT±MTX) AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PCNSL: A PROSPECTIVE, OPEN-LABEL, MULTICENTER CLINICAL TRIAL

EHA Library, Jia Song, 419272

SIGNIFICANT OUTCOME IMPROVEMENT OF THE ENTIRE R/R DLBCL POPULATION RECEIVING THIRD LINE THERAPY IN THE CAR T-CELL ERA

EHA Library, Marek Trneny, 419273

EXPLORATION OF THE OPTIMAL TREATMENT MODALITY FOR VITREORETINAL LYMPHOMA: A PRISMA COMPLIANT META-ANALYSIS AND SYSTEMATIC REVIEW

EHA Library, Liang Wang, 419274

BASELINE PET TOTAL METABOLIC TUMOR VOLUME HAS A PROGNOSTIC ROLE IN PTCLS – DATA FROM INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0

EHA Library, Tetiana Skrypets, 419275

CD22-TARGETED CAR T CELL SINGLE CELL MULTIOMIC FEATURES LINKED TO PATIENT OUTCOMES IN CD19-CAR RESISTANT LARGE B CELL LYMPHOMA

EHA Library, Anne Marijn Kramer, 419276

TUMOR MUTATIONS AND IMMUNOHISTOCHEMICAL TUMOR EXPRESSION IMPACTS SURVIVAL IN PATIENTS WITH B CELL LYMPHOMA TREATED WITH BISPECIFIC CD20XCD3 ANTIBODIES

EHA Library, Emil Kyvsgaard, 419277

UPDATED TRENDS IN REAL-WORLD OUTPATIENT (OP) ADMINISTRATION OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) IN RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Radhika Bansal, 419278

CAR-T CELL THERAPY SHOWS SIMILAR EFFICACY AND TOXICITY IN PATIENTS WITH DLBCL AGED 70 AND OLDER COMPARED TO YOUNGER PATIENTS: A MULTICENTER COHORT STUDY

EHA Library, Philipp Berning, 419279

THE PRIMARY RESULTS OF R-MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) AS THE FIRST-LINE INDUCTION THERAPY IN NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Zengjun Li, 419280

ORELABRUTINIB IN COMBINATION WITH PD-1 INHIBITOR IN REFRACTORY OR RELAPSED PRIMARY CNS LYMPHOMA

EHA Library, Yan Zhang, 419281

PHASE IB/II STUDY OF RITUXIMAB, LENALIDOMIDE, AND METHOTREXATE FOLLOWED BY LENALIDOMIDE MAINTENANCE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: THE REMLA TRIAL

EHA Library, Yan Zhang, 419282

IMPACT OF CD19 EXPRESSION BY IMMUNOHISTOCHEMISTRY IN LYMPHOMA PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL

EHA Library, Marcos Rivada, 419283

DECREASES IN LEFT VENTRICULAR FUNCTION IN ELDERLY PATIENTS WITH LARGE B-CELL LYMPHOMA RECEIVING CHOP REGIMENS IN THE RICOVER-60 TRIAL: RISK FACTORS AND OUTCOMES

EHA Library, Igor Age Kos, 419284

NIVOLUMAB CONSOLIDATION AFTER DA-EPOCH-R INDUCTION INDUCES HIGH RATES OF DISEASE-FREE AND OVERALL SURVIVAL IN PATIENTS WITH DOUBLE AND TRIPLE HIT HIGH-GRADE B-CELL LYMPHOMA

EHA Library, Martine Chamuleau, 419285

REAL-WORLD OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR TREATMENT OF RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA IN CANADA

EHA Library, Christopher Lemieux, 419286

ANATOMICAL PATTERN OF CNS RELAPSE IN AGGRESSIVE B-CELL LYMPHOMAS

EHA Library, Izel Okcu, 419287

CLINICAL CHARACTERISTICS, TREATMENTS, AND OUTCOMES OF LARGE B-CELL LYMPHOMA PATIENTS IN THIRD-LINE THERAPY INCLUDED BETWEEN 2018 AND 2023 IN THE FRENCH PROSPECTIVE MULTICENTRIC REALYSA COHORT

EHA Library, Caterina Cristinelli, 419288

EARLY PET EVALUATION AT DAY 14 POST AXICABTAGENE CILOLEUCEL INFUSION PREDICTS OUTCOME IN LARGE B-CELL LYMPHOMA: RESULTS FROM THE ALYCANTE PHASE II STUDY

EHA Library, Yassine Al Tabaa, 419289

TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: THE SPANISH GROUP OF LYMPHOMA (GELTAMO) REAL-WORLD EXPERIENCE.

EHA Library, Antonio Gutiérrez, 419290

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH TREATMENT-NAÏVE AND RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES

EHA Library, Jennifer Lue, 419291